Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger

Bleeding Clinical Trial

— OBS-PLATE  

Official title:

Changes in Central Venous Catheterization Bleeding Events After Implementing a Lower Trigger For Platelet Transfusion - an Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06187831
• Other study ID #: OBS-PLATE
• Status: Recruiting
• Start date: February 26, 2024
• Est. completion date: April 20, 2025

Study information

• Verified date: February 2024
• Source: Region Skane
• Contact: Thomas Kander, PhD
• Phone: +46 46 171163
• Email: thomas.kander[@]med.lu.se
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Central venous catheters are essential when administering treatment for hematological conditions. Many patients have a decreased platelet count which increases the risk for bleeding complications.

Baarle et al. recently published a randomized controlled study where withholding prophylactic platelet transfusions before CVC placement in patients with a platelet count of 10,000 to 50,000 per cubic millimeter did not meet the predefined margin for non-inferiority for postprocedural bleeding events (PMID: 37224197). However, bleedings grade 2 (defined as bleeding that requires external compression) were included despite lacking clinical significance.

The aim of the present study is to investigate whether lowering the preprocedural platelet transfusion trigger from 50x10^9/L to 10x10^9/L for insertions of central venous catheters remains safe with regards to postprocedural bleeding events of grade 3-4.

Description:

This is a single-center, retrospective, observational study. All adult hematologic patients receiving a central venous catheter in the department of intensive and perioperative care at Skåne University Hospital in Lund, Sweden will be eligible for inclusion.

Current Swedish guidelines recommend a pre-procedural platelet transfusion trigger of 50x10^9/L to decrease the risk of bleeding during and after the procedure. However, these guidelines are based on data from an era when the landmark technique was predominant, and the bleeding complication incidence has decreased with the widespread use of real-time ultrasound guidance. Thus, our departmental pre-procedural platelet transfusion trigger for CVC placement was lowered from 50 to 10x10^9/L in March 2023. This corresponds to the threshold commonly used in hematologic patients to prevent spontaneous bleeding.

This study is set to investigate if the incidence of grade 3-4 postprocedural bleeding events have increased after the change in platelet transfusion trigger from 50x10^9/L to 10x10^9/L before the insertion of a CVC in hematologic patients.

Approximately 110 CVCs are placed annually in hematological patients at the current institution. Retrospective data will be extracted from the electronic charts and prospective data will be collected continuously. Intervention checkpoints will be put in place to control for grade 3-4 bleeding events:

1. The transfusion trigger will remain at 10x10^9/L provided that the incidence of post-procedural grade 3-4 bleeding events in patients with a pre-procedural platelet count of 10-49 x10^9 is less than three in six months, less than four in one year or less than five in two years.

2. The transfusion trigger will be increased to 30x10^9/L if the incidence of post-procedural grade 3-4 bleeding events in patients with a pre-procedural platelet count of 10-49 x10^9 is more than two in six months, more than three in one year or more than four in two years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: April 20, 2025
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age

• Indication for central venous catheter placement.

• Patients admitted to a hematological ward at the current department

Exclusion Criteria:

• Death within 24h after insertion of CVC.

Related Conditions & MeSH terms

• Bleeding
• Central Line Complication
• Hematologic Diseases
• Hemorrhage
• Thrombocytopenia

Locations

Country	Name	City	State
Sweden	Thomas Kander	Lund	Lunds Universitet

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Kander

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of bleeding events grade 3 and 4	Incidence of bleeding events grade 3 and 4 according to the National Cancer Institute Common Terminology criteria for Adverse events (CTCAE), version 5.0.	Up to 24 hours after insertion of a central venous catheter
Secondary	Incidence of bleeding events grade 2	Incidence of bleeding events grade 2 according to the National Cancer Institute Common Terminology criteria for Adverse events (CTCAE), version 5.0	Up to 24 hours after insertion of a central venous catheter
Secondary	Number of patients receiving pre-procedural platelet transfusion Number of patients receiving pre-procedural platelet transfusion	Number of patients receiving pre-procedural platelet transfusion	From 24 hours before to 24 hours after insertion of a central venous catheter
Secondary	Number of preprocedural units of platelet transfusions	Number of preprocedural units of platelet transfusions	From 24 hours before to 24 hours after insertion of a central venous catheter